This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

First-in-Human Exploratory Single Ascending Dose of GLPG0974

This study has been completed.
Information provided by (Responsible Party):
Galapagos NV Identifier:
First received: December 16, 2011
Last updated: April 18, 2012
Last verified: April 2012

The purpose of this exploratory first-in-human study is to evaluate the amount of GLPG0974 present in the blood (pharmacokinetics) after single oral doses of GLPG0974 given to healthy subjects.

Furthermore, during the course of the study, safety and tolerability as well as the effects of GLPG0974 on mechanism of action-related parameters in the blood (pharmacodynamics) will be characterized compared to placebo.

Condition Intervention Phase
Healthy Drug: GLPG0974 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Exploratory Double-blind Placebo-controlled Study for the Assessment of Pharmacokinetics (PK), Safety, Tolerability, and Pharmacodynamics (PD) of Single Ascending Oral Doses of GLPG0974 in Healthy Subjects

Further study details as provided by Galapagos NV:

Primary Outcome Measures:
  • The amount of GLPG0974 in plasma over time after a single oral dose
    To characterize the amount of GLPG0974 in plasma over time - pharmacokinetics (PK) - after a single oral dose in healthy subjects

Secondary Outcome Measures:
  • Safety and tolerability
    To evaluate the safety and tolerability of GLPG0974 in comparison with placebo after a single oral dose in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments

  • Inhibition of CD11b on neutrophils in blood after a single oral dose of GLPG0974
    To characterize the pharmacodynamics (PD) of GLPG0974 by means of inhibition of expression of CD11b on neutrophils after a single oral dose in healthy subjects

Enrollment: 32
Study Start Date: December 2011
Study Completion Date: February 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GLPG0974 oral solution
GLPG0974 oral solution
Drug: GLPG0974
Placebo Comparator: Placebo oral solution
Placebo oral solution
Drug: GLPG0974


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male, age 18-50 years
  • BMI between 18-30 kg/m2

Exclusion Criteria:

  • Any condition that might interfere with the procedures or tests in this study
  • Drug or alcohol abuse
  • Smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01496937

SGS Stuivenberg
Antwerp, Belgium
Sponsors and Collaborators
Galapagos NV
Study Director: Frédéric Vanhoutte, MD Galapagos NV
Principal Investigator: Wouter Haazen, MD SGS Stuivenberg
  More Information

Responsible Party: Galapagos NV Identifier: NCT01496937     History of Changes
Other Study ID Numbers: GLPG0974-CL-101
Study First Received: December 16, 2011
Last Updated: April 18, 2012

Additional relevant MeSH terms:
Pharmaceutical Solutions processed this record on August 22, 2017